Significant Ownership of Logos Global Management LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Logos Global Management LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Arsani William - Managing Partner
- Manager location
- San Francisco, CA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Logos Global Management LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Logos Global Management LP
Significant Ownership of Logos Global Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | Common Stock | 9.9% | $18,407,093 | 4,435,444 | Logos Global Management LP | 23 Dec 2025 | ||
| PTN | PALATIN TECHNOLOGIES INC | Common Stock | 9.9% | $3,173,262 | +$694,535 | 182,162 | +28% | Logos Global Management LP | 31 Mar 2026 |
| ERAS | Erasca, Inc. | Common Stock | 4.8% | $29,648,000 | -$3,270,000 | 13,600,000 | -9.9% | Logos Global Management LP | 30 Sep 2025 |
| VSTM | Verastem, Inc. | Common Stock | 4.8% | $28,035,250 | -$2,207,500 | 3,175,000 | -7.3% | Logos Global Management LP | 30 Sep 2025 |
| OLMA | Olema Pharmaceuticals, Inc. | Common Stock | 4.7% | $16,172,730 | 3,208,875 | Logos Global Management LP | 18 Mar 2025 | ||
| IBIO | iBio, Inc. | Common Stock | 4.6% | $3,810,000 | -$1,270,000 | 1,500,000 | -25% | Logos Global Management LP | 31 Dec 2025 |
| DSGN | Design Therapeutics, Inc. | Common Stock | 4.4% | $16,322,350 | -$4,802,600 | 2,515,000 | -23% | Arsani William | 14 Nov 2025 |
| CBIO | CRESCENT BIOPHARMA, INC. | Ordinary Shares | 4.1% | $7,762,500 | 575,000 | Logos Global Management LP | 30 Jun 2025 | ||
| ARVN | ARVINAS, INC. | Common Stock ("Stock") | 3.4% | $21,300,000 | -$32,376,000 | 2,500,000 | -60% | Logos Global Management LP | 13 Oct 2025 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock | 3.2% | $24,136,750 | +$5,619,900 | 1,675,000 | +30% | Logos Global Management LP | 31 Mar 2026 |
| TENX | Tenax Therapeutics, Inc. | Common Stock | 3% | $11,968,000 | +$2,767,600 | 800,000 | +30% | Logos Global Management LP | 31 Mar 2026 |
| NXTC | NextCure, Inc. | Common Stock | 0% | $0 | 0 | Logos Global Management LP | 31 Dec 2024 | ||
| PRTA | PROTHENA CORP PUBLIC LTD CO | Ordinary Shares | 0% | $0 | -$18,644,000 | 0 | -100% | Logos Global Management LP | 30 Jun 2025 |
| ELEV | Elevation Oncology, Inc. | Common Stock | 0% | $0 | 0 | Logos Global Management LP | 31 Dec 2024 | ||
| ANNX | Annexon, Inc. | Common Stock | 0% | $0 | -$17,028,000 | 0 | -100% | Logos Global Management LP | 30 Jun 2025 |
| IBIO | iBio, Inc. | Common Stock | 0% | 0 | Logos Global Management LP | 31 Mar 2026 |
Schedules 13D/G Reported by Logos Global Management LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.